Drugs / Triprolizumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07028918 | Aug 2025 → Aug 2026 overdue | oral cavity squamous cell carcinoma | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07142200 | Sep 2025 → Jun 2026 overdue | bladder transitional cell carcinoma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06587802 | Mar 2025 → Mar 2027 expected | adrenal cortex carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triprolizumab | “maintenance treatment with Triprolizumab Q3W for 1 year” NCT07028918 ↗ |
| Action | Inhibit | “simultaneously block the HER2 signaling pathway and PD-1/PD-L1 signaling pathway” NCT07142200 ↗ |
| Modality | Monoclonal antibody | “PD-1 monoclonal antibody” NCT06587802 ↗ |
| Route | Intravenous | “administered intravenously” NCT06587802 ↗ |